| __timestamp | Bausch Health Companies Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 7890000 |
| Thursday, January 1, 2015 | 2682700000 | 14456000 |
| Friday, January 1, 2016 | 2810000000 | 19218000 |
| Sunday, January 1, 2017 | 2582000000 | 27986000 |
| Monday, January 1, 2018 | 2473000000 | 47928000 |
| Tuesday, January 1, 2019 | 2554000000 | 96388000 |
| Wednesday, January 1, 2020 | 2367000000 | 157743000 |
| Friday, January 1, 2021 | 2624000000 | 195293000 |
| Saturday, January 1, 2022 | 2625000000 | 237374000 |
| Sunday, January 1, 2023 | 2917000000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Bausch Health Companies Inc. over the past decade.
From 2014 to 2023, Bausch Health consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $2.9 billion in 2023. This represents a steady increase of about 44% from 2014. In contrast, Blueprint Medicines, a smaller player, exhibited a more aggressive growth in SG&A spending, skyrocketing from $7.9 million in 2014 to nearly $295 million in 2023, marking an exponential increase of over 3,600%.
These spending patterns reflect distinct strategic priorities: Bausch Health's focus on maintaining market presence and Blueprint's investment in rapid expansion and innovation.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?